Cerebrospinal and serum alpha-synuclein species as potential biomarkers for Parkinson’s disease
Please note, talk in small lecture theatre
Developing effective treatments for neurodegenerative diseases is one of the greatest medical challenges of the 21st century. Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) are very common neurological disorders of the elderly. Although many of these clinical entities have been recognized for more than a hundred years, it is only during the past fifteen years that the molecular events that precipitate the diseases have begun to be understood. Mutations in the alpha-synuclein gene cause early-onset PD, often associated with dementia. Neuropathologically these diseases are characterized by the presence of Lewy bodies, intraneuronal inclusions mostly composed of alpha-synuclein protein fibrils. Despite the progress that has been made in understanding the underlying disease mechanisms of PD and DLB, there remains an urgent need to develop methods for use in diagnosis. The development of reliable surrogate markers for the presence and abundance of alpha-synuclein lesions (Lewy bodies) in the brain would naturally facilitate a more streamlined work-up during the early care of PD and DLB patients, and importantly, allow for the biologically guided evaluation of future drug trials aimed at neuroprotection in the synucleinopathies. In this seminar, I will present the progress which has been made so far by our group to explore the use of CSF α-synuclein and its modified forms as biomarkers for PD and related disorders.
About Prof Omar El-Agnaf:
Prof. El-Agnaf is considered a pioneer in the field of Parkinson’s disease and related disorders. Several inventions have emerged from his research, and his discoveries have greatly impacted the scientific research community, provided further insight into the molecular pathogenesis of Parkinson’s disease, and offered new opportunities for the development of novel diagnostic and therapeutic tools for Parkinson’s disease. His research has also been translated into clinical studies to evaluate the potential use of α-synuclein in body fluids as diagnostic marker for Parkinson’s disease and related disorders.
23 May 2017, 16:00 (Tuesday, 5th week, Trinity 2017)
Sherrington Building, off Parks Road OX1 3PT
Sherrington Small Lecture Theatre
Prof. Omar El-Agnaf (Qatar Biomedical Research Institute)
Department of Physiology, Anatomy and Genetics (DPAG)
Melanie Witt (University of Oxford, Department of Earth Sciences, Department of Physiology Anatomy and Genetics),
Sara Bouskela (University of Oxford, Department of Physiology Anatomy and Genetics (DPAG))
Organiser contact email address:
OPDC Seminar Series (DPAG)
Members of the University only